Exclusive special offer and discount title banner vector image

MM-II OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032

MM-II Osteoarthritis Drug Pipeline: 7 Major Market’s Analysis (Market Size of MM-II in the 7 Major Markets for Osteoarthritis) Country Analysis (Japan, Germany, United States, France, Italy, Spain, United Kingdom)

REPORTS » PHARMACEUTICALS » MM-II OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032

MARKET OVERVIEW

MM-II is a new non-opioid intra-articular injection designed to alleviate knee pain in patients with osteoarthritis. This treatment utilizes the unique characteristics of proprietary multilamellar liposomes alongside an innovative mechanism of action to deliver long-lasting symptomatic relief. Extensive pre-clinical research has confirmed the safety and lubricating effects of MM-II, which help to minimize joint friction and cartilage wear. Additionally, a first-in-human study has shown that MM-II is well-tolerated and effective in reducing knee pain for osteoarthritis patients.

This drug is developed by Moebius Medical. Moebius Medical is a clinical-stage biotech company that specializes in the development of innovative medical products using its unique liposomal technologies. The company focuses on the development of novel pain-relief treatments for the treatment of osteoarthritis. Moebius Medical was founded in the year 2008 and has its headquarters in Tel Aviv, Israel.

To Know More About This Report, Request a Free Sample Copy

MARKET POTENTIAL & POSITIONING

The market outlook for MM-II, a novel non-opioid treatment for advanced osteoarthritis, especially osteoarthritis of the knee, developed by Sun Pharma and Moebius Medical, looks highly promising. With the increasing prevalence of osteoarthritis, especially among aging populations, there is a growing demand for innovative treatments. MM-II employs a proprietary suspension of large, empty multilamellar liposomes to reduce joint friction and wear, providing effective pain relief and potentially altering the progression of the disease.

Recent data from the Phase II clinical trial, presented at EULAR 2024, demonstrated that patients with symptomatic knee osteoarthritis achieved significant and sustained pain relief for up to 26 weeks after receiving a 3mL dose of MM-II. This positions MM-II as a potentially superior option in the osteoarthritis therapeutics market, particularly for patients seeking long-term relief without relying on non-steroidal anti-inflammatory drugs (NSAIDs), which, while commonly used in osteoarthritis treatment, carry their risks.

The robust clinical data also bolster the use of MM-II in therapy for osteoarthritis, highlighting its potential to reduce the need for frequent administrations. This could provide greater convenience for patients and cost savings for healthcare systems. As MM-II advances to Phase III trials and Sun Pharma pursues CE Mark approval in the European Union, the drug is anticipated to gain considerable traction in the arthritis market.

Additionally, MM-II’s innovative approach has the potential to complement current osteoarthritis rehabilitation strategies, especially for knee osteoarthritis, and enhance the overall therapeutic landscape. The application of biomarkers in ongoing research may further refine patient selection and optimize treatment outcomes.

INKWOOD RESEARCH OFFERS AN ANALYSIS OF SEVEN KEY MARKETS

United States
- According to a study on symptomatic knee osteoarthritis by the American College of Rheumatology, around 14 million people in the United States are affected by symptomatic knee osteoarthritis (OA), with advanced OA representing more than half of these cases.
- Notably, over half of those with symptomatic knee OA are under the age of 65.
- Additionally, a considerable number of individuals with diagnosed symptomatic knee OA have experienced enough disease progression to qualify for knee replacement surgery if their symptoms are severe.
Germany
France
United Kingdom
Italy
Spain
Japan

INTRODUCTION TO THE REPORT
MM-II OVERVIEW
1. PRODUCT DETAIL
2. CLINICAL DEVELOPMENT
  1. CLINICAL STUDIES
  2. CLINICAL TRIALS INFORMATION
  3. SAFETY AND EFFICACY
3. OTHER DEVELOPMENTAL ACTIVITIES
4. PRODUCT PROFILE
COMPETITIVE LANDSCAPE
1. MARKETED THERAPIES
2. LATE-STAGE EMERGING THERAPIES
MM-II MARKET ASSESSMENT
1. MARKET OUTLOOK OF MM-II IN OSTEOARTHRITIS
7 MAJOR MARKET’S ANALYSIS
1. MARKET SIZE OF MM-II IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
2. 7 COUNTRY ANALYSIS
  1. MARKET SIZE OF MM-II IN UNITED STATES FOR OSTEOARTHRITIS
  2. MARKET SIZE OF MM-II IN GERMANY FOR OSTEOARTHRITIS
  3. MARKET SIZE OF MM-II IN FRANCE FOR OSTEOARTHRITIS
  4. MARKET SIZE OF MM-II IN ITALY FOR OSTEOARTHRITIS
  5. MARKET SIZE OF MM-II IN SPAIN FOR OSTEOARTHRITIS
  6. MARKET SIZE OF MM-II IN UNITED KINGDOM FOR OSTEOARTHRITIS
  7. MARKET SIZE OF MM-II IN JAPAN FOR OSTEOARTHRITIS
SWOT ANALYSIS
ANALYST PERSPECTIVE

LIST OF TABLES

TABLE 1: MM-II, CLINICAL TRIAL DESCRIPTION, 2024

TABLE 2: MM-II, GENERAL DESCRIPTION

TABLE 3: MARKETED THERAPIES

TABLE 4: EMERGING THERAPIES

TABLE 5: MM-II MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)

TABLE 6: MM-II MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)

TABLE 7: MM-II MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)

TABLE 8: MM-II MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)

TABLE 9: MM-II MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)

TABLE 10: MM-II MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)

TABLE 11: MM-II MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)

TABLE 12: MM-II MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

LIST OF FIGURES

FIGURE 1: MM-II MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)

FIGURE 2: MM-II MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)

FIGURE 3: MM-II MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)

FIGURE 4: MM-II MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)

FIGURE 5: MM-II MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)

FIGURE 6: MM-II MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)

FIGURE 7: MM-II MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)

FIGURE 8: MM-II MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

FAQs

Is MM-II a painkiller?

MM-II is not a conventional painkiller. Rather, it addresses the underlying causes of pain in osteoarthritis by enhancing joint lubrication and reducing cartilage wear, resulting in prolonged pain relief.

Is MM-II available to the public?

MM-II is currently in clinical trials, including Phase III studies. While it is not yet widely available, it is anticipated to enter the market after completing successful trials and obtaining regulatory approvals.

How does MM-II work?

MM-II works by leveraging the physical properties of multilamellar liposomes, which act as a lubricant within the joint. This reduces friction and wear on the cartilage, helping to ease pain and improve joint function over time.